Interview with Stephen Turley, Managing Director, Lundbeck Limited (UK)
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
Address: Magdalen Centre The Oxford Science Park Oxford OX4 4GA,United Kingdom
Tel: +44 (0)1865 784574
Web: http://www.circassia.co.uk/
Circassia is a specialty biopharmaceutical company focused on developing world-class immunotherapies. These include a new class of T-cell vaccines designed to treat a broad range of allergies, and therapies to combat autoimmune conditions such as rheumatoid arthritis and psoriasis. The Company has made rapid progress since its establishment in 2006, and several of its products are currently in mid- to late-stage development, having successfully completed a number of phase II clinical studies.
Circassia has a broad portfolio of immuno-based therapies, with many currently progressing through clinical development. The company has completed a number of successful phase II studies and plans to advance several products into the final stage of development in the near future.
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish…
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan…
This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last…
See our Cookie Privacy Policy Here
